What are the two gates?
Two permission systems govern every pharmacy advertisement, and conflating them is among the more costly errors observed in the sector. The first is platform policy. Google treats healthcare as a restricted vertical, requires online pharmacies to hold recognised certification before advertisements serve, and applies further policies governing permissible claims, formats and targeting. The second is statutory. UK medicines legislation applies to a paid search advertisement precisely as it applies to any other advertisement, the prohibition on promoting prescription-only medicines to the public included, and the MHRA has demonstrated on multiple occasions that paid search falls within its monitoring.
Approval of an advertisement by Google confers nothing under the Human Medicines Regulations. Automated review will, with some regularity, admit campaigns which would attract regulatory correspondence, whilst simultaneously rejecting entirely lawful advertisements owing to classifier error. The two systems should therefore be operated as separate compliance checklists, and neither treated as a proxy for the other. This comes as no surprise, given that platform policies are drafted to manage commercial and reputational exposure across many jurisdictions, whereas the statutory position reflects a single legislature's view of what may be promoted to the public.
How is platform clearance obtained?
The sequence follows the dual-gate structure set out in the certification guide. Recognised certification is obtained first, an application for healthcare advertising is then submitted to Google evidencing that certification, and account-level clearances follow. Timelines are measured in weeks rather than days, which is the rationale for initiating the process alongside acquiring applications rather than at the point of launch.
Two maintenance requirements warrant emphasis. Certification must remain current, since lapse suspends advertising and jeopardises payment processing concurrently, both being dependent on the same instrument. Further, the advertising account's registered particulars, business name and domain, must correspond exactly to the certified entity. Discrepancies are interpreted by systems designed to detect circumvention as evidence of precisely that.
Which campaign architectures are defensible?
Three architectures are consistently defensible under both permission systems. Service campaigns bid on service-intent queries, terms such as "online weight management clinic" or "private travel consultation", with advertisement copy promoting the consultation rather than any medicine. Condition education campaigns address informational intent with genuinely educational content, within the constraints of the advertising rules, and supply the upper funnel rather than compressing prospective patients toward the lower. Brand campaigns defend the pharmacy's own name at comparatively low cost, capturing demand generated by brand investment which would otherwise accrue to competing bidders.
No defensible architecture exists for product campaigns on prescription lines. POM names deployed as keywords, supported by advertisements communicating price and availability, contravene both systems simultaneously. It is worth noting that the commercial argument aligns with the regulatory one, as it does throughout this library. Operators achieving durable returns from paid search compete on the service layer, whereas the product layer resolves into public price competition whose principal beneficiary is the platform.
What constraints govern copy and keyword selection?
Copy. No POM should be named in a promotional context, no pricing or offer should attach to a prescription medicine, no efficacy claim should exceed the licensed indication or the supporting evidence, and comparative before-and-after presentation should be avoided. A practical test is to compose each headline on the assumption that the MHRA's advertising unit constitutes the second reader, which, over a sufficient period, it does.
Keywords. Bidding should be confined to intent which can be lawfully answered. Service and condition terms constitute the principal estate, the pharmacy's own brand terms represent defensive expenditure, and competitor brand terms are a commercial decision subject to trade mark considerations. Product-name terms are where judgement is most exercised, since platform acceptance of a bid does not license the advertisement or landing page to convert that query into promotion of the medicine. The conservative architecture, in which product-term traffic is answered by service-level advertisements and educational content, is both the defensible position and, in the authors' observation, the more productive one, given that a searcher entering a drug name is typically still in an informational phase and the advertiser who addresses that phase secures the subsequent consultation.
How should the account be constructed?
Account structure should follow intent, with a single service or condition per advertisement group, such that each advertisement corresponds closely to both its keyword set and its landing page. This correspondence serves two ends simultaneously, quality score improvement and compliance control, which is an unusually convenient alignment. Match types should be initially restrictive, exact and phrase, and broadened only as the search terms report establishes what is genuinely being queried. Broad match in a regulated vertical functions as a mechanism for purchasing queries which would not have been approved had they been proposed.
The negative keyword list warrants elevation from administrative housekeeping to compliance instrument. Terms including "without prescription" and "no prescription", together with their variants, should be excluded at account level from inception. The campaign then neither answers nor pays for unlawful intent, and the resulting search terms report remains defensible on inspection, an outcome of some value given that every query for which payment was made represents a query the advertiser elected to answer.
Conversion measurement should be configured with the health data position in mind. Events should be recorded at a generic level, consultation initiated and booking completed, with condition identifiers excluded from analytics payloads and from URL structures, since a tracking implementation transmitting "weight-loss checkout" has disclosed health-adjacent information to an advertising platform. The measurement stack should be constructed on the assumption that the network layer is subject to inspection, which it is.
Why is remarketing unavailable?
Google's personalised advertising policies prohibit targeting constructed from sensitive interest categories, health among them. Remarketing audiences derived from service pages are therefore unavailable, as are customer-match uploads of patient email addresses and lookalike audiences seeded from either. The data protection position is concordant. An audience list comprising visitors to weight-management pages constitutes the segmentation problem reproduced at the tracking layer.
The appropriate response is architectural rather than adversarial. Pharmacy paid search operates as an intent channel, in which demand is met at the point of query and either converted or informed, whilst the retention function is discharged by an email programme operating on lawfully obtained consent. Attempts to reconstruct remarketing capability through indirect means constitute circumvention under both permission systems concurrently, and are well represented among the accounts which subsequently require the remediation described below.
What is required of the landing page?
The landing page forms part of the advertisement and is reviewed as such by Google and, where relevant, by the MHRA. It should function as the entry point to the consultation pathway rather than a means of bypassing it, with the service accurately described, registration and prescriber transparency visible, assessment preceding payment, pricing presented as a service charge, and no POM promotion irrespective of the qualification of the traffic.
The craft lies in matching page to intent without compromising any of the above. Service queries should resolve to service pages, informational queries to educational content with a clearly signposted onward route, and no query should resolve directly to a checkout. Page performance, mobile-first construction and the trust indicators discussed in the consultation flow guide perform the conversion function which copy is not permitted to perform through overstatement.
What of Shopping and Performance Max?
Shopping campaigns retain a lawful application. GSL and general retail lines may be presented in the product feed and promoted as the ordinary commerce they are. P medicines require case-by-case assessment of presentation, whilst POMs should be excluded from feeds entirely, without exception, notwithstanding that feed tooling will typically ingest them without objection. Each feed row constitutes an advertisement and should be audited accordingly.
Performance Max warrants considerably greater caution. Its automation assembles creative, placements and audiences from supplied assets with limited transparency and correspondingly limited control, which in a regulated vertical entails combinations which were never reviewed appearing in contexts which were never selected. Where it is deployed at all, it should be constrained to retail-only feeds, with assets curated such that any permutation would satisfy both permission systems, brand exclusions configured, and placement reports examined rather than filed. For the clinical side of the business, manually structured search campaigns remain the recommendation, on the straightforward basis that in this vertical control is not a stylistic preference but the compliance model itself.
What are the economics?
Certification restricts the eligible advertiser population, yet those remaining compete for commercially valuable intent, and cost per click reflects that competition rather than the restriction. Quality score becomes materially significant in consequence, since relevance and landing page experience generate discounts which compound across an account, furnishing a further argument for tight structural correspondence. The only defensible yardstick, however, is that proposed in the playbook, namely acquisition cost evaluated against retention-modelled lifetime value, since an identical click may be uneconomic for a single transaction whilst comfortably profitable for a service exhibiting sustained renewal.
Two disciplines preserve the channel's integrity. Paid traffic should accelerate a funnel already demonstrated to convert owned demand, and should not be deployed to establish whether that funnel converts, since discovery through paid media both exhausts budget and, more consequentially, generates the conversion pressure under which compliance gates erode. Secondly, quality indicators should be reviewed alongside volume indicators at the weekly cadence, refusal rates within paid cohorts and dispute rates by traffic source among them, on the basis that traffic which converts and subsequently churns or disputes has been paid for twice.
How should suspension be handled?
Healthcare accounts are suspended with some frequency, occasionally on substantive grounds and frequently through automated determination, and the remediation pathway transposes directly from the payments context. Diagnosis precedes response. The cited policy is read, the advertisements, keywords and landing pages are audited against it as an external reviewer would audit them, and the substantive issue is corrected before any appeal is submitted. A single appeal, specifying the correction and evidencing it, is materially more effective than repeated identical submissions, which train the review process against the advertiser.
Circumvention should be avoided absolutely. New accounts, variant domains and third-party profiles are detected by the same identity-matching which operates in payments, and convert a recoverable policy determination into a durable exclusion attached to the business and its officers. The parallel with the account-loss guide is exact, and so is the prophylaxis, which is to remain declared, certified, with particulars corresponding, and campaigns constructed such that they would survive human review under either permission system on an unfavourable day.
Key takeaways
- Two permission systems govern every advertisement, platform policy and statute, and clearance under one implies nothing under the other.
- Certification precedes platform application, the process runs to weeks, and lapse suspends advertising and jeopardises payments concurrently.
- Service, education and brand campaigns are defensible, whilst product campaigns on POM terms contravene both systems simultaneously.
- Product-name queries should be answered with service-level advertisements and educational content, which is both the defensible and the more productive position.
- Negative keyword lists function as compliance instruments, and conversion tracking should exclude condition identifiers from payloads and URLs.
- Health-based remarketing is prohibited under both platform policy and data protection law, with retention discharged through consented email instead.
- Evaluate acquisition cost against retention-modelled lifetime value, accelerate only proven funnels, and remediate suspensions substantively rather than through circumvention.
FAQs
Both systems, satisfied separately.
Paid acquisition returns are determined largely by what the traffic lands on: compliant landing pages, a consultation pathway constructed to standard, and a retention function capable of justifying the click. Our publisher builds the pages and campaign architecture, whilst Dataforge PMR operates the pathway behind them. Where click costs appear to exceed returns, the funnel is usually the variable worth examining first.
See Dataforge PMR